Genomic Analysis of the Prognostic Value of Colony-stimulating Factors (CSFs) and Colony-stimulating Factor Receptors (CSFRs) Across 24 Solid Cancer Types

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Sep 21

PMID 32953794

Citations 5

Authors

Xinyi Huang

Pingping Hu

Jiandong Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The prognostic roles of granulocyte-/granulocyte-macrophage colony-stimulating factor (G-/GM-CSF) and its receptors (CSFRs) from the genomic perspective remain controversial. The aim of our study was to evaluate their prognostic value in multiple cancer types by analyzing omics data.

Methods: The omics data of G-/GM-CSF and receptors were obtained from the cBioportal database. Cutoff values were determined by X-tile. Overall survival (OS) was assessed by Kaplan-Meier curves. Differentially expressed genes (DEGs) and common regulated genes were analyzed using R software and Venny 2.1.0, while enrichment pathway analyses were performed by Metascape.

Results: A comprehensive mRNA analysis was performed in 8,565 patients across 24 cancer types. The combination subgroup of CSF2 and its receptors with high expression and favorable prognosis was associated with the activation of immune-related pathways, while the subgroup with unfavorable prognosis was associated with the activation of inflammatory and cellular pathways. As for the combination subgroup of CSF3 and its receptor, the high expression and poor prognosis subgroup was accompanied by the activation of inflammation and signaling transduction pathways.

Conclusions: The prognostic value of CSFs and CSFRs are cancer-type dependent. Therefore, personalized risk stratification based on CSF and CSFR pathway should be considered for cancer patients.

Citing Articles

Establishment of two oxaliplatin-resistant gallbladder cancer cell lines and comprehensive analysis of dysregulated genes.

Guo H, Zhi Y, Wang K, Li N, Yu D, Ji Z Open Med (Wars). 2023; 18(1):20230690.

PMID: 37786776 PMC: 10541806. DOI: 10.1515/med-2023-0690.

A Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer.

Jiang W, Ouyang X, Jiang C, Yin L, Yao Q, Pei X Int J Mol Sci. 2023; 24(6).

PMID: 36982170 PMC: 10049685. DOI: 10.3390/ijms24065091.

Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p.

Vadevoo S, Gunassekaran G, Yoo J, Kwon T, Hur K, Chae S Front Immunol. 2022; 13:976196.

PMID: 36483544 PMC: 9724234. DOI: 10.3389/fimmu.2022.976196.

Poly(ADP)-Ribosylation Inhibition: A Promising Approach for Clear Cell Renal Cell Carcinoma Therapy.

Karpova Y, Guo D, Makhov P, Haines A, Markov D, Kolenko V Cancers (Basel). 2021; 13(19).

PMID: 34638458 PMC: 8507656. DOI: 10.3390/cancers13194973.

Comprehensive Characterization of Cachexia-Inducing Factors in Diffuse Large B-Cell Lymphoma Reveals a Molecular Subtype and a Prognosis-Related Signature.

Kuang Z, Li X, Liu R, Chen S, Tu J Front Cell Dev Biol. 2021; 9:648856.

PMID: 34079795 PMC: 8166255. DOI: 10.3389/fcell.2021.648856.

References

Zarei S, Schwenter F, Luy P, Aurrand-Lions M, Morel P, Kopf M . Role of GM-CSF signaling in cell-based tumor immunization. Blood. 2009; 113(26):6658-68. PMC: 2943756. DOI: 10.1182/blood-2008-06-161075. View

Gutschalk C, Herold-Mende C, Fusenig N, Mueller M . Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res. 2006; 66(16):8026-36. DOI: 10.1158/0008-5472.CAN-06-0158. View

Urdinguio R, Fernandez A, Moncada-Pazos A, Huidobro C, Rodriguez R, Ferrero C . Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res. 2012; 73(1):395-405. DOI: 10.1158/0008-5472.CAN-12-0806. View

Wang H, Jia R, Zhao T, Li X, Lang M, Lan C . RETRACTED: HIF-1α mediates tumor-nerve interactions through the up-regulation of GM-CSF in pancreatic ductal adenocarcinoma. Cancer Lett. 2019; 453:10-20. DOI: 10.1016/j.canlet.2019.03.036. View

Mueller M, Fusenig N . Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. Int J Cancer. 1999; 83(6):780-9. DOI: 10.1002/(sici)1097-0215(19991210)83:6<780::aid-ijc14>3.0.co;2-c. View

Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M . Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007; 25(18):2546-53. DOI: 10.1200/JCO.2006.08.5829. View

Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4(1):11-22. DOI: 10.1038/nrc1252. View

Parmiani G, Castelli C, Pilla L, Santinami M, Colombo M, Rivoltini L . Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2006; 18(2):226-32. DOI: 10.1093/annonc/mdl158. View

Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C . Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer. 2003; 106(1):34-44. DOI: 10.1002/ijc.11188. View

10.

Creelan B, Antonia S, Noyes D, Hunter T, Simon G, Bepler G . Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013; 36(8):442-50. PMC: 3846277. DOI: 10.1097/CJI.0b013e3182a80237. View

11.

Wang T, Wu B, Hu X, Liu J, Zhang T, Li F . A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients. Ann Transl Med. 2019; 7(9):196. PMC: 6545320. DOI: 10.21037/atm.2019.04.10. View

12.

Hollmen M, Karaman S, Schwager S, Lisibach A, Christiansen A, Maksimow M . G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer. Oncoimmunology. 2016; 5(3):e1115177. PMC: 4839343. DOI: 10.1080/2162402X.2015.1115177. View

13.

Morris K, Khan H, Ahmad A, Weston L, Nofchissey R, Pinchuk I . G-CSF and G-CSFR are highly expressed in human gastric and colon cancers and promote carcinoma cell proliferation and migration. Br J Cancer. 2014; 110(5):1211-20. PMC: 3950854. DOI: 10.1038/bjc.2013.822. View

14.

Wei X, Chan S, Kwek S, Lewis J, Dao V, Zhang L . Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016; 4(11):948-958. PMC: 5115633. DOI: 10.1158/2326-6066.CIR-16-0042. View

15.

Jinushi M, Nakazaki Y, Dougan M, Carrasco D, Mihm M, Dranoff G . MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. 2007; 117(7):1902-13. PMC: 1884688. DOI: 10.1172/JCI30966. View

16.

Shiomi A, Usui T . Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm. 2015; 2015:568543. PMC: 4370199. DOI: 10.1155/2015/568543. View

17.

Dranoff G . GM-CSF-secreting melanoma vaccines. Oncogene. 2003; 22(20):3188-92. DOI: 10.1038/sj.onc.1206459. View

18.

Touw I, van de Geijn G . Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front Biosci. 2006; 12:800-15. DOI: 10.2741/2103. View

19.

Bo L, Wang F, Zhu J, Li J, Deng X . Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care. 2011; 15(1):R58. PMC: 3221991. DOI: 10.1186/cc10031. View

20.

Tachibana M, Murai M . G-CSF production in human bladder cancer and its ability to promote autocrine growth: a review. Cytokines Cell Mol Ther. 1998; 4(2):113-20. View